ReviewCureus2026
Management of Tibial Adamantinoma: Balancing Oncologic Cure and Reconstructive Longevity.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Well-differentiated tibial adamantinoma is a rare, low-grade malignant bone tumor primarily located in the anterior portion of the proximal two-thirds of the tibia and characterized by a biphasic histology. Because of its significant resistance to both radiotherapy and systemic chemotherapy, achieving local control and long-term survival strictly relies on surgical intervention. To evaluate these interventions, a review of English-language literature across PubMed/MEDLINE, Google Scholar, and the Cochrane Library was conducted, focusing on long-term retrospective studies, multicenter series, and case reports. This review assesses oncological and functional outcomes, specifically analyzing the incidence of late tumor recurrence and the durability of complex limb-salvage reconstructive procedures. The literature indicates that en bloc resection with wide safety margins remains the treatment of choice, demonstrating a significantly lower rate of local recurrence compared to intralesional curettage. Although the 10-year overall survival rate is highly favorable, adamantinoma exhibits a characteristically prolonged latency period, with local recurrences and pulmonary or lymphatic metastases commonly emerging 15 to 20 years postoperatively. Furthermore, the extensive intercalary tibial defects resulting from wide resections pose substantial reconstructive challenges. Long-term complications - such as aseptic non-union, deep infection, and progressive structural graft fatigue - are common in limb-salvage constructs utilizing massive structural allografts, vascularized fibular autografts, or hybrid techniques, often necessitating multiple complex revision surgeries. Ultimately, while en bloc resection offers the most consistent oncologic cure despite its reconstructive complexity, effective long-term management mandates lifelong monitoring for delayed metastasis alongside proactive surveillance for mechanical failure in limb-salvage reconstructions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.